Business Description
Imugene Ltd
ISIN : AU000000IMU9
Total Employee Number:
5Description
Imugene Ltd is an Australian-headquartered clinical stage cell therapy company developing an Allogeneic CAR T for blood cancers. Its lead asset is an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. The lead asset, azer-cel, is an allogeneic CAR T cell therapy targeting CD19 positive cancer cells. Autologous CAR T therapies, which use the patient's own modified T cells, azer-cel uses donor-derived T cells that are genetically engineered to attack cancer cells. The group has identified one reportable segment, being the research and development of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.42 | |||||
Equity-to-Asset | 0.39 | |||||
Debt-to-Equity | 0.7 | |||||
Debt-to-EBITDA | -0.06 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -19.6 | |||||
3-Year EPS without NRI Growth Rate | -11.5 | |||||
3-Year FCF Growth Rate | -29.9 | |||||
3-Year Book Growth Rate | -36.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 68.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.65 | |||||
9-Day RSI | 37.09 | |||||
14-Day RSI | 36.31 | |||||
3-1 Month Momentum % | -6.86 | |||||
6-1 Month Momentum % | -63.74 | |||||
12-1 Month Momentum % | -67.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.7 | |||||
Quick Ratio | 0.7 | |||||
Cash Ratio | 0.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.4 | |||||
Shareholder Yield % | -54.39 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -329.5 | |||||
ROA % | -181.32 | |||||
ROIC % | -192.75 | |||||
3-Year ROIIC % | -355.21 | |||||
ROC (Joel Greenblatt) % | -4486.87 | |||||
ROCE % | -263.4 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.45 | |||||
Price-to-Tangible-Book | 3.7 | |||||
EV-to-EBIT | -0.32 | |||||
EV-to-EBITDA | -0.34 | |||||
EV-to-Forward-Revenue | 223.48 | |||||
EV-to-FCF | -0.75 | |||||
Earnings Yield (Greenblatt) % | -312.5 | |||||
FCF Yield % | -148.67 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Imugene Ltd Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.19 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 69.03 | ||
| 14-Day RSI | 36.31 | ||
| 14-Day ATR (€) | 0.002049 | ||
| 20-Day SMA (€) | 0.043375 | ||
| 12-1 Month Momentum % | -67.24 | ||
| 52-Week Range (€) | 0.0365 - 0.306 | ||
| Shares Outstanding (Mil) | 557.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Imugene Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Imugene Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| 0.0294118:1 Stock Split | 2025-07-02 | 0.24 (+0.00%) |
Show
Entries
Imugene Ltd Frequently Asked Questions
What is Imugene Ltd(FRA:ILA)'s stock price today?
The current price of FRA:ILA is €0.04. The 52 week high of FRA:ILA is €0.31 and 52 week low is €0.04.
When is next earnings date of Imugene Ltd(FRA:ILA)?
The next earnings date of Imugene Ltd(FRA:ILA) is .
Does Imugene Ltd(FRA:ILA) pay dividends? If so, how much?
Imugene Ltd(FRA:ILA) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers